Advancing the Development of Pediatric Therapeutics: Successes and Challenges of Performing Long-Term Pediatric Safety Studies; Public Workshop, 13375-13376 [2016-05621]
Download as PDF
Federal Register / Vol. 81, No. 49 / Monday, March 14, 2016 / Notices
the Office of Management and Budget
(OMB) under the Paperwork Reduction
Act of 1995 (44 U.S.C. 3501–3520). The
collection of information in 21 CFR part
312 has been approved under 0910–
0014; the collection of information in 21
CFR part 314 has been approved under
0910–0001; the collection of
information in 21 CFR part 601 has been
approved under 0910–0338; and the
collection of information for
applications submitted under section
351(k) of the PHS Act has been
approved under 0910–0719. In
accordance with the PRA, before
publication of the final guidance
document, FDA intends to solicit public
comment and obtain OMB approval for
any information collections
recommended in this guidance that are
new or that would represent material
modifications to previously approved
collections of information found in FDA
regulations or guidances.
III. Electronic Access
Persons with access to the Internet
may obtain the document at https://
www.fda.gov/Drugs/Guidance
ComplianceRegulatoryInformation/
Guidances/default.htm, https://
www.fda.gov/BiologicsBloodVaccines/
GuidanceComplianceRegulatory
Information/default.htm or https://
www.regulations.gov.
Dated: March 8, 2016.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2016–05626 Filed 3–11–16; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2016–N–0001]
Advancing the Development of
Pediatric Therapeutics: Successes and
Challenges of Performing Long-Term
Pediatric Safety Studies; Public
Workshop
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice of public workshop.
The Food and Drug
Administration’s (FDA) Office of
Pediatric Therapeutics (OPT) and Center
for Drug Evaluation and Research are
announcing a 2-day public workshop
entitled ‘‘Advancing the Development of
Pediatric Therapeutics (ADEPT):
Successes and Challenges of Performing
Long-Term Pediatric Safety Studies.’’
The purpose of this 2-day public
workshop is for FDA to have an open
jstallworth on DSK7TPTVN1PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
18:20 Mar 11, 2016
Jkt 238001
discussion with experts in the field
examining the need and path forward
for long-term pediatric safety studies.
Day 1 of the public workshop will focus
on an exposition of the successes and
challenges of long-term safety studies in
children. Day 2 of the public workshop
will focus on suggestions for the future
on study design and implementation of
long-term safety studies in children.
Viewpoints of patient representatives of
children with chronic conditions and
industry will be included.
DATES: The public workshop will be
held on April 13 and 14, 2016, from 8
a.m. to 5 p.m. See the SUPPLEMENTARY
INFORMATION section for registration date
and information.
ADDRESSES: The public workshop will
be held at The DoubleTree by Hilton
Hotel—Bethesda, 8120 Wisconsin Ave.,
Bethesda, MD 20814.
FOR FURTHER INFORMATION CONTACT:
Renan A. Bonnel, Office of Pediatric
Therapeutics, Food and Drug
Administration, 10903 New Hampshire
Ave., Silver Spring, MD 20993–0002,
301–796–8654, FAX: 301–847–8640,
email: renan.bonnel@fda.hhs.gov.
SUPPLEMENTARY INFORMATION:
I. Background
Medical product safety studies in
children are usually performed for 6
months or less. In children,
measurement of long-term outcomes is
particularly challenging since,
compared to adults, children are
undergoing dramatic growth and
developmental changes. This 2-day
public workshop will focus on the
challenges of long-term follow-up in
children receiving medical products.
The first day of the public workshop
will focus on the problems or barriers,
including; challenges with study design,
data capture, infrastructure, and
endpoints. Viewpoints of parents and
industry will be represented. The
second day of the public workshop will
include panel discussions to propose
solutions to the problems posed on day
one and to discuss the epidemiological
challenges posed by the collection of
data on different types of adverse
events. On both days of the public
workshop there will be a certain amount
of time on the agenda for attendee
questions or comments.
II. Participation in the Public
Workshop
Registration: There is no fee to attend
the public workshop, but attendees
should register in advance. Space is
limited, and registration will be on a
first-come, first-served basis. Persons
interested in attending this workshop
PO 00000
Frm 00066
Fmt 4703
Sfmt 4703
13375
must register online at: https://pediatric
safety.eventbrite.com before April 7,
2016. For those without Internet access,
please contact Renan A. Bonnel (see FOR
FURTHER INFORMATION CONTACT) to
register. In the event that a minimum
number of participants have not
registered, the workshop will be
postponed. Registered participants will
be notified of any change. Onsite
registration will be available if seating
permits it. Registration information, the
agenda, and additional background
materials can be found at https://www.
fda.gov/NewsEvents/Meetings
ConferencesWorkshops/
ucm477639.htm.
If you need special accommodations
due to a disability, please contact Renan
A. Bonnel (see FOR FURTHER INFORMATION
CONTACT) at least 7 days in advance.
Persons attending the meeting are
advised that FDA is not responsible for
providing access to electrical outlets.
Web cast: The live Web cast on April
13, 2016, will be available at: https://
event.webcasts.com/starthere.jsp
?ei=1093258. After the morning session,
users will be automatically redirected to
the afternoon link. Should you lose
connection over lunch, please use the
following link for the afternoon session
(note that it is different from the
morning’s session): https://event.
webcasts.com/starthere.jsp?ei=1093259.
On April 14, 2016, the live Web cast
will be available at: https://event.
webcasts.com/starthere.jsp?ei=1093263.
After the morning session, users will be
automatically redirected to the
afternoon link. Should you lose
connection over lunch, please use the
following link for the afternoon session
(note that it is different from the
morning’s session): https://event.
webcasts.com/starthere.jsp?ei=1093265.
The Web cast will only be for listening
and there will not be an opportunity for
Web cast participants to speak.
The videocast will be posted after the
workshop at https://www.fda.gov/News
Events/MeetingsConferencesWorkshops/
ucm477639.htm.
Transcripts: Transcripts of the
workshop will be available for review at
the Division of Dockets Management
(HFA–305), Food and Drug
Administration, 5630 Fishers Lane, Rm.
1061, Rockville, MD 20852, and at
https://www.regulations.gov
approximately 30 days after the
workshop. A transcript will also be
available in either hard copy or on CD–
ROM, after submission of a Freedom of
Information request. Send written
requests to the Division of Freedom of
Information. The Freedom of
Information address is available on the
Agency’s Web site at
E:\FR\FM\14MRN1.SGM
14MRN1
13376
Federal Register / Vol. 81, No. 49 / Monday, March 14, 2016 / Notices
https://www.fda.gov. Send faxed requests
to 301–827–9267.
Dated: March 8, 2016.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2016–05621 Filed 3–11–16; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2016–N–0001]
The Fifth Annual Food and Drug
Administration-International Society
for Pharmaceutical Engineering
Quality Conference
AGENCY:
The meeting will be held at
the Bethesda North Marriott Hotel &
Conference Center, 5701 Marinelli Rd.,
Bethesda, MD 20852.
FOR FURTHER INFORMATION CONTACT:
Susan Krys, ISPE, 7200 Wisconsin Ave.,
Suite 305, Bethesda, MD 20814, 301–
364–9202, FAX: 240–204–6024, email:
skrys@ispe.org, or Sau (Larry) Lee, 301–
796–2905, email: Sau.Lee@fda.hhs.gov.
ADDRESSES:
Food and Drug Administration,
HHS.
ACTION:
Evaluation and Research, in cosponsorship with the International
Society for Pharmaceutical Engineering
(ISPE), is announcing a meeting entitled
‘‘Fifth Annual FDA–ISPE Quality
Conference.’’ The purpose of the
meeting is to discuss manufacturing,
compliance, and management practices
that create, implement, and sustain a
culture of high quality and result in
reliable pharmaceutical and biologic
products that support patient health.
DATES: The meeting will be held on June
6, 7, and 8, 2016, from 8:30 a.m. to 4
p.m.
Notice of meeting.
The Food and Drug
Administration’s (FDA) Center for Drug
SUMMARY:
ISPE is an
association of engineers, scientists,
manufacturing, quality, and industrial
professionals involved in the
development, manufacture, quality
control, and regulation of
pharmaceuticals and related products.
This co-sponsored meeting facilitates
discussion and problem solving around
technical, quality, compliance, and
other manufacturing issues.
Registration: There is a registration fee
to attend this meeting. The registration
fee is charged to help defray the costs
of programming and facilities. Seats are
limited, and registration will be on a
first-come, first-served basis.
To register, please complete
registration online at https://
www.ispe.org/events. FDA has verified
the Web address, but FDA is not
responsible for subsequent changes to
the Web site after this document
publishes in the Federal Register. The
costs of registration for the different
categories of attendees are as follows:
SUPPLEMENTARY INFORMATION:
Category
Cost
jstallworth on DSK7TPTVN1PROD with NOTICES
Industry Representatives:
ISPE Members ........................................................................................................................................
Non-members ..........................................................................................................................................
Academic ........................................................................................................................................................
Government ....................................................................................................................................................
Accommodations: Attendees are
responsible for their own hotel
accommodations. Attendees making
reservations at the Bethesda North
Marriott Hotel & Conference Center in
Bethesda, MD are eligible for a reduced
rate of $209 USD, not including
applicable taxes. To receive the reduced
rate, contact the Bethesda North
Marriott Hotel (1–301–822–9200 or 1–
800–859–8003) and identify yourself as
an attendee of the meeting. If you need
special accommodations due to a
disability, please contact Susan Krys at
least 7 days in advance.
Transcripts: We expect that
transcripts will be available
approximately 30 days after the
meeting. A transcript will be available
in either hard copy or on CD–ROM, after
submission of a Freedom of Information
request. The Freedom of Information
office address is available on the
Agency’s Web site at https://
www.fda.gov. Send faxed requests to
301–827–9267.
Dated: March 8, 2016.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2016–05627 Filed 3–11–16; 8:45 am]
BILLING CODE 4164–01–P
VerDate Sep<11>2014
18:20 Mar 11, 2016
Jkt 238001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2016–N–0001]
Peripheral and Central Nervous
System Drugs Advisory Committee;
Notice of Meeting
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
This notice announces a forthcoming
meeting of a public advisory committee
of the Food and Drug Administration
(FDA). The meeting will be open to the
public.
Name of Committee: Peripheral and
Central Nervous System Drugs Advisory
Committee.
General Function of the Committee:
To provide advice and
recommendations to the Agency on
FDA’s regulatory issues.
Date and Time: The meeting will be
held on April 25, 2016, from 8 a.m. to
5:30 p.m. This meeting is a reschedule
of a postponed meeting announced in
the Federal Register of December 18,
2015 (80 FR 79047), originally
scheduled for January 22, 2016.
PO 00000
Frm 00067
Fmt 4703
Sfmt 4703
$1,895 (early-bird); $2,095 (onsite).
$2,275 (early-bird); $2,475 (onsite).
$1,425 (early-bird); $1,575 (onsite).
$700 (early-bird); $700 (onsite).
Location: College Park Marriott Hotel
and Conference Center, Chesapeake
Ballroom, 3501 University Blvd. East,
Hyattsville, MD 20783. The conference
center’s telephone number is 301–985–
7300.
Contact Person: Moon Hee V. Choi,
Center for Drug Evaluation and
Research, Food and Drug
Administration, 10903 New Hampshire
Ave., Bldg. 31, Rm. 2417, Silver Spring,
MD 20993–0002, 301–796–9001, FAX:
301–847–8533, email: PCNS@
fda.hhs.gov, or FDA Advisory
Committee Information Line, 1–800–
741–8138 (301–443–0572 in the
Washington, DC area). A notice in the
Federal Register about last minute
modifications that impact a previously
announced advisory committee meeting
cannot always be published quickly
enough to provide timely notice.
Therefore, you should always check the
Agency’s Web site at https://
www.fda.gov/AdvisoryCommittees/
default.htm and scroll down to the
appropriate advisory committee meeting
link, or call the advisory committee
information line to learn about possible
modifications before coming to the
meeting.
Agenda: The committee will discuss
new drug application (NDA) 206488,
E:\FR\FM\14MRN1.SGM
14MRN1
Agencies
[Federal Register Volume 81, Number 49 (Monday, March 14, 2016)]
[Notices]
[Pages 13375-13376]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-05621]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2016-N-0001]
Advancing the Development of Pediatric Therapeutics: Successes
and Challenges of Performing Long-Term Pediatric Safety Studies; Public
Workshop
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice of public workshop.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration's (FDA) Office of Pediatric
Therapeutics (OPT) and Center for Drug Evaluation and Research are
announcing a 2-day public workshop entitled ``Advancing the Development
of Pediatric Therapeutics (ADEPT): Successes and Challenges of
Performing Long-Term Pediatric Safety Studies.'' The purpose of this 2-
day public workshop is for FDA to have an open discussion with experts
in the field examining the need and path forward for long-term
pediatric safety studies. Day 1 of the public workshop will focus on an
exposition of the successes and challenges of long-term safety studies
in children. Day 2 of the public workshop will focus on suggestions for
the future on study design and implementation of long-term safety
studies in children. Viewpoints of patient representatives of children
with chronic conditions and industry will be included.
DATES: The public workshop will be held on April 13 and 14, 2016, from
8 a.m. to 5 p.m. See the SUPPLEMENTARY INFORMATION section for
registration date and information.
ADDRESSES: The public workshop will be held at The DoubleTree by Hilton
Hotel--Bethesda, 8120 Wisconsin Ave., Bethesda, MD 20814.
FOR FURTHER INFORMATION CONTACT: Renan A. Bonnel, Office of Pediatric
Therapeutics, Food and Drug Administration, 10903 New Hampshire Ave.,
Silver Spring, MD 20993-0002, 301-796-8654, FAX: 301-847-8640, email:
renan.bonnel@fda.hhs.gov.
SUPPLEMENTARY INFORMATION:
I. Background
Medical product safety studies in children are usually performed
for 6 months or less. In children, measurement of long-term outcomes is
particularly challenging since, compared to adults, children are
undergoing dramatic growth and developmental changes. This 2-day public
workshop will focus on the challenges of long-term follow-up in
children receiving medical products. The first day of the public
workshop will focus on the problems or barriers, including; challenges
with study design, data capture, infrastructure, and endpoints.
Viewpoints of parents and industry will be represented. The second day
of the public workshop will include panel discussions to propose
solutions to the problems posed on day one and to discuss the
epidemiological challenges posed by the collection of data on different
types of adverse events. On both days of the public workshop there will
be a certain amount of time on the agenda for attendee questions or
comments.
II. Participation in the Public Workshop
Registration: There is no fee to attend the public workshop, but
attendees should register in advance. Space is limited, and
registration will be on a first-come, first-served basis. Persons
interested in attending this workshop must register online at: https://pediatricsafety.eventbrite.com before April 7, 2016. For those without
Internet access, please contact Renan A. Bonnel (see FOR FURTHER
INFORMATION CONTACT) to register. In the event that a minimum number of
participants have not registered, the workshop will be postponed.
Registered participants will be notified of any change. Onsite
registration will be available if seating permits it. Registration
information, the agenda, and additional background materials can be
found at https://www.fda.gov/NewsEvents/MeetingsConferencesWorkshops/ucm477639.htm.
If you need special accommodations due to a disability, please
contact Renan A. Bonnel (see FOR FURTHER INFORMATION CONTACT) at least
7 days in advance. Persons attending the meeting are advised that FDA
is not responsible for providing access to electrical outlets.
Web cast: The live Web cast on April 13, 2016, will be available
at: https://event.webcasts.com/starthere.jsp?ei=1093258. After the
morning session, users will be automatically redirected to the
afternoon link. Should you lose connection over lunch, please use the
following link for the afternoon session (note that it is different
from the morning's session): https://event.webcasts.com/starthere.jsp?ei=1093259. On April 14, 2016, the live Web cast will be
available at: https://event.webcasts.com/starthere.jsp?ei=1093263.
After the morning session, users will be automatically redirected to
the afternoon link. Should you lose connection over lunch, please use
the following link for the afternoon session (note that it is different
from the morning's session): https://event.webcasts.com/starthere.jsp?ei=1093265. The Web cast will only be for listening and
there will not be an opportunity for Web cast participants to speak.
The videocast will be posted after the workshop at https://www.fda.gov/NewsEvents/MeetingsConferencesWorkshops/ucm477639.htm.
Transcripts: Transcripts of the workshop will be available for
review at the Division of Dockets Management (HFA-305), Food and Drug
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852, and
at https://www.regulations.gov approximately 30 days after the workshop.
A transcript will also be available in either hard copy or on CD-ROM,
after submission of a Freedom of Information request. Send written
requests to the Division of Freedom of Information. The Freedom of
Information address is available on the Agency's Web site at
[[Page 13376]]
https://www.fda.gov. Send faxed requests to 301-827-9267.
Dated: March 8, 2016.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2016-05621 Filed 3-11-16; 8:45 am]
BILLING CODE 4164-01-P